LLY

1,042.27

-1.11%↓

JNJ

246.2

+0.25%↑

ABBV

228.42

-0.4%↓

NVS

166.68

+1.33%↑

MRK

123.89

+0.15%↑

LLY

1,042.27

-1.11%↓

JNJ

246.2

+0.25%↑

ABBV

228.42

-0.4%↓

NVS

166.68

+1.33%↑

MRK

123.89

+0.15%↑

LLY

1,042.27

-1.11%↓

JNJ

246.2

+0.25%↑

ABBV

228.42

-0.4%↓

NVS

166.68

+1.33%↑

MRK

123.89

+0.15%↑

LLY

1,042.27

-1.11%↓

JNJ

246.2

+0.25%↑

ABBV

228.42

-0.4%↓

NVS

166.68

+1.33%↑

MRK

123.89

+0.15%↑

LLY

1,042.27

-1.11%↓

JNJ

246.2

+0.25%↑

ABBV

228.42

-0.4%↓

NVS

166.68

+1.33%↑

MRK

123.89

+0.15%↑

Kodu・Aktsiate loetelu・Voyager Therapeutics Inc

Voyager Therapeutics Inc

Suletud

3.77 5.31

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

3.52

Max

3.86

Põhinäitajad
By Trading Economics
Sissetulek	5.5M -28M
Müük	8.2M 13M
Kasumimarginaal	-208.694
Töötajad	172
EBITDA	8.7M -27M

Soovitused
By TipRanks
Soovitused	Tugev "osta" hinnang
12 kuu keskmine prognoos	+339.26% upside

Dividendid
By Dow Jones
Järgmine tulemuste avaldamine	10. märts 2026

Turustatistika
By TradingEconomics
Turukapital	-66M 188M
Eelmine avamishind	-1.54
Eelmine sulgemishind	3.77

Tehniline skoor

By Trading Central

Kindlus

Bearish Evidence

3.17 / 3.4644 Toetus ja vastupanu

Voyager Therapeutics Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

23. veebr 2026, 22:53 UTC

Omandamised, ülevõtmised, äriostud

Keurig Dr Pepper Raises Additional $1.5 Billion in Deal to Split Company

23. veebr 2026, 22:36 UTC

Tulu

Kratos Defense & Security Solutions 4Q Profit Rises; Sees Federal Shutdown Denting 1Q -- Update

23. veebr 2026, 22:32 UTC

Tulu

Woodside Energy Fiscal Year Net Profit Falls 24%

23. veebr 2026, 23:58 UTC

Market Talk

Tulu

Plenty of Questions for Woodside Despite Well-Guided Result -- Market Talk

23. veebr 2026, 23:58 UTC

Market Talk

Tulu

Global Energy Roundup: Market Talk

23. veebr 2026, 23:47 UTC

Market Talk

Scentre's Share Price Slips as Earnings Guidance Underwhelms -- Market Talk

23. veebr 2026, 23:43 UTC

Market Talk

Gold Edges Higher Amid Ongoing Tariff Risks -- Market Talk

23. veebr 2026, 23:41 UTC

Omandamised, ülevõtmised, äriostud

Crescent Capital Partners Owns 53% of ClearView Wealth

23. veebr 2026, 23:40 UTC

Omandamised, ülevõtmised, äriostud

ClearView Wealth Says Crescent Capital Partners Intends to Support Deal

23. veebr 2026, 23:40 UTC

Omandamised, ülevõtmised, äriostud

ClearView Wealth Says Directors Unanimously Recommend Shareholders Vote in Favor of Deal

23. veebr 2026, 23:40 UTC

Market Talk

Nikkei May Rise as Investors Assess Tariff Developments -- Market Talk

23. veebr 2026, 23:40 UTC

Omandamised, ülevõtmised, äriostud

ClearView Wealth Says Zurich Insurance Offering A$0.65/Share in Cash

23. veebr 2026, 23:39 UTC

Omandamised, ülevõtmised, äriostud

ClearView Wealth Agrees to Takeover by Zurich Insurance Group Unit

23. veebr 2026, 23:31 UTC

Tulu

United Overseas Bank 2025 Total Dividend S$1.56/Shr >U11.SG

23. veebr 2026, 23:31 UTC

Tulu

United Overseas Bank Proposes Final Dividend of S$0.71/Shr Vs. S$0.92/Shr >U11.SG

23. veebr 2026, 23:28 UTC

Tulu

United Overseas Bank 4Q Net Interest Income S$2.35B Vs. S$2.45B >U11.SG

23. veebr 2026, 23:28 UTC

Tulu

United Overseas Bank 4Q Oper Pft S$1.76B Vs. Pft S$1.88B >U11.SG

23. veebr 2026, 23:28 UTC

Tulu

United Overseas Bank 4Q Total Income S$3.29B Vs. S$3.46B >U11.SG

23. veebr 2026, 23:27 UTC

Tulu

United Overseas Bank 4Q Net S$1.41B Vs. Net S$1.52B >U11.SG

23. veebr 2026, 23:24 UTC

Market Talk

Major Miners On Whole Delivered Positive Earnings Season -- Market Talk

23. veebr 2026, 22:38 UTC

Omandamised, ülevõtmised, äriostud

Keurig Dr Pepper Raises Additional $1.5B in Deal to Split Company

23. veebr 2026, 22:31 UTC

Tulu

Hims & Hers Stock Falls. Why Earnings Are Underwhelming Investors. -- Barrons.com

23. veebr 2026, 22:24 UTC

Tulu

Viva Energy Energy & Infrastructure Ebitda A$93 Million

23. veebr 2026, 22:22 UTC

Tulu

Viva Energy FY Commercial & Industrial Ebitda A$460.5 Million

23. veebr 2026, 22:22 UTC

Tulu

Viva Energy FY Convenience & Mobility Ebitda A$197.4 Million

23. veebr 2026, 22:22 UTC

Tulu

Viva Energy FY Underlying Ebitda A$700.9 Million

23. veebr 2026, 22:22 UTC

Tulu

Viva Energy Final Dividend 3.94 Australian Cents/Security

23. veebr 2026, 22:21 UTC

Tulu

Viva Energy FY Revenue A$28.53 Billion, Down 1.1%

23. veebr 2026, 22:21 UTC

Tulu

Viva Energy FY Replacement-Cost Net Profit A$183.6 Million, Down 28%

23. veebr 2026, 22:20 UTC

Tulu

Viva Energy FY Historical-Cost Net Loss A$421.1 Million

Võrdlus sarnastega

Hinnamuutus

Voyager Therapeutics Inc Prognoos

Hinnasiht

By TipRanks

339.26% tõus

12 kuu keskmine prognoos

Keskmine 15.33 USD 339.26%

Kõrge 25 USD

Madal 10 USD

Põhineb 3 Wall Streeti analüütiku instrumendi Voyager Therapeutics Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

3 ratings

Osta

Hoia

Müü

Põhineb 3 analüütiku instrumendi Voyager Therapeutics Inc aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

3.17 / 3.4644Toetus ja vastupanu

Recent bearish events outweigh bullish events.

All events are bearish.

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Voyager Therapeutics Inc

Voyager Therapeutics, Inc., a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial. In addition, the company develops VY-FXN01, which is in preclinical trial to treat friedreich's ataxia; and GBA1 gene replacement to treat parkinson's disease and is in preclinical trial. Further, it provides research program for the treatment of Huntington's disease. The company has collaboration and license agreements with Alexion; AstraZeneca Rare Disease; Novartis Pharma AG; Neurocrine Biosciences, Inc; and Sangamo Therapeutics, Inc. Voyager Therapeutics, Inc. was incorporated in 2013 and is headquartered in Lexington, Massachusetts.